Atrasentan: targeting the endothelin axis in prostate cancer

Bibliography

• GRONBERG H: Prostate cancer epidemiology. Lancet (2003) 361:859–864.
   PubMed Web of Science ®Google Scholar
• TANNOCK IF, DE WIT R, BERRY WR et al.: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl. Med. (2004) 351:1502–1512.
   PubMed Web of Science ®Google Scholar
• PETRYLAK DP, TANGEN CM, HUSSAIN MH et al.: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl. Med. (2004) 351:1513–1520.
   PubMed Web of Science ®Google Scholar
• FOX E, CURT GA, BALIS FM: Clinical trial design for target-based therapy. Oncologist (2002) 7:401–409.
   PubMed Web of Science ®Google Scholar
• RUBIN SA, LEVIN ER: Clinical review 53: the endocrinology of vasoactive peptides: synthesis to function. Clin. Endocrinol Metab. (1994) 78:6–10.
   Google Scholar
• BREMNES T, PAASCHE JD, MEHLUM A, SANDBERG C, BREMNES B, ATTRAMADAL H: Regulation and intracellular trafficking pathways of the endothelin receptors. Biol. Chem. (2000) 275:17596–17604.
   Web of Science ®Google Scholar
• LEVIN ER: Endothelins. N Engl. I Med. (1995) 333:356–363.
   PubMed Web of Science ®Google Scholar
• GRAY GA, WEBB DJ: The endothelin system and its potential as a therapeutic target in cardiovascular disease. Pharmacol Pier. (1996) 72:109–148.
   Google Scholar
• BAGNATO A, NATALI PG: Endothelin receptors as novel targets in tumor therapy. J. Trans]. Med. (2004) 2:16.
   PubMedGoogle Scholar
• OBARA K, KOIDE M, ISHIKAWA T, TANABE Y, NAKAYAMA K: Protein kinase CS but not PKCE activity is involved in contractile potentiation by endothelin-1 in the porcine coronary artery. Cardiovasc. Pharmacol (2000) 36:S120–S121.
   PubMed Web of Science ®Google Scholar
• DAUB H, WEISS FU, WALLASCH C, ULLRICH A: Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature (1996) 379:557–560.
   PubMed Web of Science ®Google Scholar
• JIANG ZY, ZHOU QL, CHATTERJEE A et al.: Endothelin-1 modulates insulin signaling through phosphatidylinositol 3-kinase pathway in vascular smooth muscle cells. Diabetes (1999) 48:1120–1130.
   PubMed Web of Science ®Google Scholar
• BATTISTINI B, CHAILLER P, D'ORLEANS-JUSTE P, BRIERE N, SIROIS P: Growth regulatory properties of endothelins. Peptides (1993) 14:385–399.
   PubMed Web of Science ®Google Scholar
• VACCA F, BAGNATO A, CATT KJ, TECCE R: Transactivation of the epidermal growth factor receptor in endothelin-1-induced mitogenic signaling in human ovarian carcinoma cells. Cancer Res. (2000) 60:5310–5317.
   PubMed Web of Science ®Google Scholar
• CLARKE JG, BENJAMIN N, LARKIN SW, WEBB DJ, DAVIES GJ, MASERI A: Endothelin is a potent long-lasting vasoconstrictor in men. Am. J. Physiol (1989) 257:H2033–H2035.
   PubMed Web of Science ®Google Scholar
• REMUZZI G, PERICO N, BENIGNI A: New therapeutics that antagonize endothelin: promises and frustrations. Nat. Rev Drug Discov (2002) 1:986–1001.
   PubMed Web of Science ®Google Scholar
• TOUYZ RM, SCHIFFRIN EL: Role of endothelin in human hypertension. Can. .1. Physiol Pharmacol (2003) 81:533–541.
   PubMed Web of Science ®Google Scholar
• NELSON J, BAGNATO A, BATTISTINI B, NISEN P: The endothelin axis: emerging role in cancer. Nat. Rev Cancer (2003) 3:110–116.
   PubMed Web of Science ®Google Scholar
• NELSON JB, HEDICAN SP, GEORGE DJ et al.: Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat. Med. (1995) 1:944–949.
   PubMed Web of Science ®Google Scholar
• ••The seminal paper that stated the relevanceof the endothelin axis in the pathophysiology of prostate cancer.
   Google Scholar
• NELSON JB, CHAN-TACK K, HEDICAN SP et al.: Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res. (1996) 56:663–668.
   PubMed Web of Science ®Google Scholar
• PAPANDREOU CN, USMANI B, GENG Y et al.: Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nat. Med. (1998) 4:50–57.
   Google Scholar
• NELSON JB, LEE WH, NGUYEN SH et al.: Methylation of the 5'CpG island of the endothelin B receptor gene is common in human prostate cancer. Cancer Res. (1997) 57:35–37.
   PubMed Web of Science ®Google Scholar
• •Relevant manuscript that addresses the mechanisms of ETB abnormal regulation in prostate cancer.
   Google Scholar
• USMANI BA, HARDEN B, MAITLAND NJ, TURNER AJ: Differential expression of neutral endopeptidase-24.11 (neprilysin) and endothelin-converting enzyme in human prostate cancer cell lines. Clin. Sci. (2002) 103\(Suppl. 48):3145–3175.
   Google Scholar
• SALANI D, DI CASTRO V, NICOTRA MR et al: Role of endothelin-1 in neovascularization of ovarian carcinoma. Am. J. Pathol (2000) 157:1537–1547.
   PubMed Web of Science ®Google Scholar
• KOPETZ ES, NELSON JB, CARDUCCI MA: Endothelin-1 as a target for therapeutic intervention in prostate cancer. Invest. New Drugs (2002) 20:173–182.
   PubMed Web of Science ®Google Scholar
• EBERL LP, VALDENAIRE 0, SAINTGIORGIO V, JEANNIN JF, JUILLERAT-JEANNERET L: Endothelin receptor blockade potentiates FasL-induced apoptosis in rat colon carcinoma cells. Int. J. Cancer (2000) 86:182–187.
   PubMed Web of Science ®Google Scholar
• DEL BUFALO D, DI CASTRO V, BIROCCIO A et al: Endothelin-1 protects ovarian carcinoma cells against paclitaxel-induced apoptosis: requirement for Akt activation. Mol Pharmacol (2002) 61:524–532.
   PubMed Web of Science ®Google Scholar
• DEL BUFALO D, DI CASTRO V, BIROCCIO A et al: Endothelin-1 acts as a 1638 Expert Op/n. Investig. Drugs (2004)13(12) survival factor in ovarian carcinoma cells. Clin. Sd. (2002) 103\(Suppl. 48):302S–305S.
   Google Scholar
• ROSANO L, VARMI M, SALANI D et al: Endothelin-1 induces tumor proteinase activation and invasiveness of ovarian carcinoma cells. Cancer Res. (2001) 61:8340–8346.
   PubMed Web of Science ®Google Scholar
• ROSANO L, SALANI D, DI CASTRO V, SPINELLA F, NATALI PG, BAGNATO A: Endothelin-1 promotes proteolytic activity of ovarian carcinoma. Clin. Sd. (2002) 103\(Suppl. 48):3065–3095.
   Google Scholar
• ROSANO L, SPINELLA F, DI CASTRO V et al.: Endothelin receptor blockade inhibits molecular effectors of Kaposi's sarcoma cell invasion and tumor growth M vivo. Am. j Pathol (2003) 163:753–762.
   Google Scholar
• BAGNATO A, ROSANO L, SPINELLA F,DI CASTRO V, TECCE R, NATALI PG: Endothelin B receptor blockade inhibits dynamics of cell interactions and communications in melanoma cell progression. Cancer Res. (2004) 64:1436–1443.
   PubMed Web of Science ®Google Scholar
• SPINELLA F, ROSANO L, DI CASTRO V, NICOTRA MR, NATALI PG, BAGNATO A: Endothelin-1 decreases gap junctional intercellular communication by inducing phosphorylation of connexin 43 in human ovarian carcinoma cells. J. Biol. Chem. (2003) 278:41294–41301.
   PubMed Web of Science ®Google Scholar
• SALANI D, TARABOLETTI G, ROSANO L et al: Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Am. j Path& (2000) 157:1703–1711.
   PubMed Web of Science ®Google Scholar
• SPINELLA F, ROSANO L, DI CASTRO V, NATALI PG, BAGNATO A: Endothelin-1 induces vascular endothelial growth factor by increasing hypcoda-inducible factor-1a in ovarian carcinoma cells. Biol. Chem. (2002) 277:27850–27855.
   Web of Science ®Google Scholar
• •An elegant paper describing the link between the endothelin axis and new vessel formation in ovarian cancer models.
   Google Scholar
• SPINELLA F, ROSANO L, DI CASTRO V, NICOTRA MR, NATALI PG, BAGNATO A: Inhibition of cyclooxygenase-1 and -2 expression by targeting the endothelin a receptor in human ovarian carcinoma cells. OM. Cancer Res. (2004) 10:4670-4679. A relevant paper describing the link between the endothelin axis and COX-2 modulation in ovarian cancer models.
   Google Scholar
• GUPTA S, SRIVASTAVA M, AHMAD N, BOSTWICK DG, MUKHTAR H: Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate (2000) 42:73–78.
   PubMed Web of Science ®Google Scholar
• PRUTHI RS, DERKSEN JE, MOORE D: A pilot study of use of the cyclooxygenase-2 inhibitor celecoxib in recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. BIU Int. (2004) 93:275–278.
   Google Scholar
• NELSON JB, NGUYEN SH, WU-WONG JR et al: New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade. Urology (1999) 53:1063–1069.
   PubMed Web of Science ®Google Scholar
• CHIAO JW, MOONGA BS, YANG YM et al.: Endothelin-1 from prostate cancer cells is enhanced by bone contact which blocks osteoclastic bone resorption. Br. J. Cancer (2000) 83:360–365.
   PubMed Web of Science ®Google Scholar
• ••An elegant series of experiments leading tothe establishment of the basis of the prostate cancer cell-bone interaction.
   Google Scholar
• YIN JJ, MOHAMMAD KS, KAKONEN SM et al.: A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc. Natl. Acad. Sri. USA (2003) 100:10954–10959.
   PubMed Web of Science ®Google Scholar
• GUISE TA, YIN JJ, MOHAMMAD KS: Role of endothelin-1 in osteoblastic bone metastases. Cancer (2003) 97:779–784.
   PubMed Web of Science ®Google Scholar
• POMONIS JD, ROGERS SD, PETERS CM, GHILARDI JR, MANTYH PW: Expression and localization of endothelin receptors: implications for the involvement of peripheral glia in nociception. Neurosci. (2001) 21:999–1006.
   PubMed Web of Science ®Google Scholar
• JARVIS MF, WESSALE JL, ZHU CZ et al:ABT-627, an endothelin ET(A) receptor-selective antagonist, attenuates tactile allodynia in a diabetic rat model of neuropathic pain. Ear: .1. Pharmacol (2000) 388:29–35.
   Google Scholar
• YUYAMA H, KOAKUTSU A, FUJIYASU N et al.: Effects of selective endothelin ET(A) receptor antagonists on endothelin-l-induced potentiation of cancer pain. Ear: Pharmacol (2004) 492:177–182.
   PubMed Web of Science ®Google Scholar
• •In vivo evidence of the role of ET-1 in pain modulation.
   Google Scholar
• KHODOROVA A, NAVARRO B, JOUAVILLE LS et al.: Endothelin-B receptor activation triggers an endogenous analgesic cascade at sites of peripheral injury. Nat. Med. (2003) 9:1055–1061.
   PubMed Web of Science ®Google Scholar
• WU-WONG JR, DIXON DB, CHIOU WJ et al.: Pharmacology of endothelin receptor antagonists ABT-627, ABT-546, A-182086 and A-192621: in vitro studies. Clin. Sci. (2002) 103\(Suppl. 48):1075-111S.
   Google Scholar
• ZHU T, ANDRE A, FACEY I et al.: Effectof ketoconazole (KET) on the pharmacokinetics (PK) of atrasentan (ABT-627, ATN). Proceedings of the 40th American Socieg, of Clinical Oncology annual meeting. New Orleans, LA, USA (2004) Abstract 4727.
   Google Scholar
• XIONG H, JANKOWSKI J, ASHBRENNER E et al: Effect of rifampin (RIF) on the pharmacokinetics (PK) of atrasentan (ABT-627, ATN). Proceedings of the 40th American Society of Clinical Oncology annual meeting. New Orleans, LA, USA (2004) Abstract 4728.
   Google Scholar
• KLEIN CE, SCHROEDER MC, FACEY I et al.: Effect of atrasentan (ABT-627, ATN) on the pharmacokinetics (PK) of fexofenadine (FEM. Proceedings of the 40th American Socieg, of Clinical Oncology annual meeting. New Orleans, LA, USA (2004) Abstract 4723.
   Google Scholar
• KATZ DA, GRIMM DR, CARR R et al: Pharmacogenetic meta-analysis suggests that atrasentan is an organic anion transport protein C substrate. Clin. Pharm. The]: (2004) (2004) 75:94.
   Google Scholar
• SAMARA E, DUTTA S, CAO G, GRANNEMAN GR, DORDAL MS, PADLEY RJ: Single-dose pharmacokinetics of atrasentan, an endothelin-A receptor antagonist. Clin. Pharmacol (2001) 41:397–403.
   Google Scholar
• ••The first evaluation of atrasentanadministration in humans.
   Google Scholar
• CARDUCCI MA, NELSON JB, BOWLING MK et al: Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics. I Clin. Oncol (2002) 20:2171–2180.
   PubMed Web of Science ®Google Scholar
• ZONNENBERG BA, GROENEWEGEN G, JANUS TJ et al.: Phase I dose-escalation study of the safety and pharmacokinetics of atrasentan: an endothelin receptor antagonist for refractory prostate cancer. Clin. Cancer Res. (2003) 9:2965–2972.
   PubMed Web of Science ®Google Scholar
• RYAN CW, VOGELZANG NJ, VOKES EE et al.: Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies. Clio. Cancer Res. (2004) 10:4406–4411.
   PubMed Web of Science ®Google Scholar
• CARDUCCI MA, PADLEY RJ, BREUL J et al.: Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, Phase II, placebo-controlled trial. ./. Clio. °pea (2003) 21:679–689.
   Google Scholar
• ••The first report of a clinical trial assessingthe efficacy of atrasentan in patients with prostate cancer.
   Google Scholar
• NELSON JB, NABULSI AA, VOGELZANG NJ et al.: Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan. Um]. (2003) 169:1143–1149.
   Web of Science ®Google Scholar
• •An elegant paper showing the translational research results of the Phase II trial of atrasentan in prostate cancer patients.
   Google Scholar
• CARDUCCI MA, NELSON JB, SAAD F et al.: Effects of atrasentan on disease progression and biological markers in men with metastatic hormone-refractory prostate cancer: Phase III study. Proceedings of the 40th American Society of Clinical Oncology annual meeting. New Orleans, LA, USA (2004) Abstract 4508. Preliminary results of the first Phase III trial of atrasentan in prostate cancer patients.
   Google Scholar